Peter Greenberg

Clinical Focus

• Cancer> Hematology
• Hematology
• Myelodysplastic Syndromes

Administrative Appointments

• Director, Stanford MDS Center (1998 - 2011)
• Head, Hematology Section, VA Palo Alto Health Care System (1979 - 2005)
• Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 - 1979)

Honors and Awards

• International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)

Professional Education

Community and International Work

• Chair, Committee on International Outreach, 1998-2001 

Internet Links

• http://hematology.stanford.edu/

Current Research Interests

The major direction of research in my laboratory is to determine the role and mechanisms of hemopoietic dysregulation in human myeloid malignancies. The relation between molecular changes and cellular phenotype / pathophysiology is being explored using microarray and next generation technologies to evaluate differential gene expression profiles of MDS and AML marrow cells. The impact of cytokines and biologic response modifiers on these molecular features and hemopoietic response is being examined in clinical investigations with MDS and AML patients in therapeutic clinical trials with these agents.

Clinical Trials

• Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003 Recruiting
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO) Recruiting
• Phase III of ON 01910.Na in Myelodysplastic Syndrome Recruiting
• A Study of Darbepoetin Alfa in Patients with Myelodysplastic Syndrome (MDS) Completed
• Determination of Safe and Effective Dose of AMG 531 in Subjects With MDS Receiving Hypomethylating Agents Completed

Publications

• Personal omics profiling reveals dynamic molecular and medical phenotypes. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O''Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M. Cell. 2012; 148 (6): 1293-307
• Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Leuk Res. 2012; 36 (1): 98-103
• Molecular and genetic features of myelodysplastic syndromes. Greenberg PL, Int J Lab Hematol. 2011
• Myelodysplastic syndromes: dissecting the heterogeneity. Greenberg PL, J Clin Oncol. 2011; 29 (15): 1937-8
• NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P. J Natl Compr Canc Netw. 2011; 9 (1): 30-56